1. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, Burgess E, Jindal K, Barrett B, Singer J, Djurdjev O. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin.
Am J Kidney Dis 34:1999;125–134.
2. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients.
J Am Soc Nephrol 10:1999;610–619.
3. Ofsthun N, Labrecque J, Lacson E, Keen M, Lazarus JM. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients.
Kidney Int 63:2003;1908–1914.
4. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease.
J Am Soc Nephrol 16:2005;2180–2189.
5. Locatelli F, Pisoni RL, Akizawa T, Cruz JM, DeOreo PB, Lameire NH, Held PJ. Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) findings.
Am J Kidney Dis 44:2004;27–33.
6. Freburger JK, Ng LJ, Bradbury BD, Kshirsagar AV, Brookhart MA. Changing patterns of anemia management in US hemodialysis patients.
Am J Med 125:2012;906–914.e9.
7. Jin DC. Current status of dialysis therapy in Korea.
Korean J Intern Med 26:2011;123–131.
8. Kidney Disease Outcomes Quality Initiative (KDOQI): KDOQI Clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease. 2007 update of hemoglobin target.
Am J Kidney Dis 50:2007;471–530.
9. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2:2012;279–335.
10. http://www.nhis.or.kr/portal/site/main/MENU_WBDDC04.
11. Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, Strippoli GF. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis.
JAMA 305:2011;1119–1127.
12. Terrier N, Jaussent I, Dupuy AM, Morena M, Delcourt C, Chalabi L, Rouanet C, Canaud B, Cristol JP. Creatinine index and transthyretin as additive predictors of mortality in haemodialysis patients.
Nephrol Dial Transplant 23:2008;345–353.
13. Collins AJ, Li S, St. Peter W, Ebben J, Roberts T, Ma JZ, Manning W. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%.
J Am Soc Nephrol 12:2001;2465–2473.
14. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, Greenland S, Kalantar-Zadeh K. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients.
J Am Soc Nephrol 17:2006;1181–1191.
15. Messana JM, Chuang CC, Turenne M, Wheeler J, Turner J, Sleeman K, Tedeschi P, Hirth R. Association of quarterly average achieved hematocrit with mortality in dialysis patients: a time-dependent comorbidity-adjusted model.
Am J Kidney Dis 53:2009;503–512.
16. Santos PR, Melo AD, Lima MM, Negreiros IM, Miranda JS, Pontes LS, Rabelo GM, Viana AC, Alexandrino MT, Barros FA, Neto BR, Brito AA, Da Silva Costa A. Mortality risk in hemodialysis patients according to anemia control and erythropoietin dosing.
Hemodial Int 15:2011;493–500.
17. Brookhart MA, Schneeweiss S, Avorn J, Bradbury BD, Liu J, Winkelmayer WC. Comparative mortality risk of anemia management practices in incident hemodialysis patients.
JAMA 303:2010;857–864.
18. Horl WH. Anaemia management and mortality risk in chronic kidney disease.
Nat Rev Nephrol 9:2013;291–301.
19. Goodkin DA, Fuller DS, Robinson BM, Combe C, Fluck R, Mendelssohn D, Akizawa T, Pisoni RL, Port FK. Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients.
J Am Soc Nephrol 22:2011;358–365.
20. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D. Correction of anemia with epoetin alfa in chronic kidney disease.
N Engl J Med 355:2006;2085–2098.
21. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.
N Engl J Med 339:1998;584–590.
22. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A. Normalization of hemoglobin level in patients with chronic kidney disease and anemia.
N Engl J Med 355:2006;2071–2084.
23. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
N Engl J Med 361:2009;2019–2032.
24. http://www.fda.gov/Drugs/DrugSafety/ucm259639.htm.
25. Park SK, Hwang KS, Park JS, Lee CH, Kang CM, Kim GH. Hemoglobin variability associated with different erythropoiesis stimulating agents in hemodialysis patients. Korean J Nephrol 30:2011;41–47.
26. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
Am J Kidney Dis 52:2008;519–530.